241 related articles for article (PubMed ID: 37490232)
1. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
Khatri VM; Mills MN; Oliver DE; Yu HM; Vogelbaum MA; Forsyth PA; Soliman HH; Han HS; Ahmed KA
J Neurooncol; 2023 Aug; 164(1):191-197. PubMed ID: 37490232
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
3. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU; Murthy RK; Abramson V; Anders C; Bachelot T; Bedard PL; Borges V; Cameron D; Carey LA; Chien AJ; Curigliano G; DiGiovanna MP; Gelmon K; Hortobagyi G; Hurvitz SA; Krop I; Loi S; Loibl S; Mueller V; Oliveira M; Paplomata E; Pegram M; Slamon D; Zelnak A; Ramos J; Feng W; Winer E
JAMA Oncol; 2023 Feb; 9(2):197-205. PubMed ID: 36454580
[TBL] [Abstract][Full Text] [Related]
4. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
[TBL] [Abstract][Full Text] [Related]
5. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Lin NU; Borges V; Anders C; Murthy RK; Paplomata E; Hamilton E; Hurvitz S; Loi S; Okines A; Abramson V; Bedard PL; Oliveira M; Mueller V; Zelnak A; DiGiovanna MP; Bachelot T; Chien AJ; O'Regan R; Wardley A; Conlin A; Cameron D; Carey L; Curigliano G; Gelmon K; Loibl S; Mayor J; McGoldrick S; An X; Winer EP
J Clin Oncol; 2020 Aug; 38(23):2610-2619. PubMed ID: 32468955
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
7. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
8. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
Tam M; Narayana A; Raza S; Kunnakkat S; Golfinos JG; Parker EC; Novik Y
Med Oncol; 2014 Feb; 31(2):832. PubMed ID: 24390418
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
Mills MN; Naz A; Thawani C; Walker C; Figura NB; Kushchayev S; Oliver DE; Etame AB; Yu HM; Robinson TJ; Liu JKC; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 May; 21(1):552. PubMed ID: 33992087
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.
Upadhyay R; Klamer BG; Perlow HK; White JR; Bazan JG; Jhawar SR; Blakaj DM; Grecula JC; Arnett A; Mestres-Villanueva MA; Healy EH; Thomas EM; Chakravarti A; Raval RR; Lustberg M; Williams NO; Palmer JD; Beyer SJ
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201564
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
[TBL] [Abstract][Full Text] [Related]
12. Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis.
Depner JF; Berg T; Ejlertsen B; Andreasen LW; Møller S; Maraldo MV
Acta Oncol; 2023 Nov; 62(11):1502-1510. PubMed ID: 37750329
[TBL] [Abstract][Full Text] [Related]
13. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Metzger Filho O; Leone JP; Li T; Tan-Wasielewski Z; Trippa L; Barry WT; Younger J; Lawler E; Walker L; Freedman RA; Tolaney SM; Krop I; Winer EP; Lin NU
Ann Oncol; 2020 Sep; 31(9):1231-1239. PubMed ID: 32461105
[TBL] [Abstract][Full Text] [Related]
15. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
16. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
[TBL] [Abstract][Full Text] [Related]
18. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
19. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery for intracranial hemangiopericytomas: a multicenter study.
Cohen-Inbar O; Lee CC; Mousavi SH; Kano H; Mathieu D; Meola A; Nakaji P; Honea N; Johnson M; Abbassy M; Mohammadi AM; Silva D; Yang HC; Grills I; Kondziolka D; Barnett GH; Lunsford LD; Sheehan J
J Neurosurg; 2017 Mar; 126(3):744-754. PubMed ID: 27104850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
